Nearly 30 representatives yesterday urged House leaders to modify in the next COVID-19 response package impending thresholds for qualifying participants in Advanced Alternative Payment Models, which they said threaten to “derail” the movement to value-based care under the Medicare Access and CHIP Reauthorization Act.

“It has become clear that COVID-19 will make it more challenging for many of these providers to meet the law’s current thresholds due to shifts in care,” the House members wrote. “According to data recently released by the Centers for Medicare & Medicaid Services, on average, providers missed even the current QP threshold (50%) and are nowhere near the heightened threshold (75%) required by statute in 2021. It is critical for seniors that APMs continue in 2021 and beyond. Providers participating in APMs are conducting care coordination strategies that are needed now more than ever.”

Reps. Suzan DelBene, D-Wash., Roger Marshall, R-Kan., Peter Welch, D-Vt., and Darin LaHood, R-Ill., spearheaded the letter with support from AHA and other national hospital and physician organizations.

Related News Articles

Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…
Headline
The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the state’s 340B contract pharmacy law…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Chairperson's File
Public
Advocacy is a core part of the work of the AHA, protecting and sustaining what hospitals and health systems need to truly care for our communities. We often…
Headline
A U.S. District Court for the District of Columbia judge June 27 ruled against Johnson & Johnson and sided with the Department of Health and Human Services…
Headline
The AHA June 16 released a report showing hospitals that participated in the 340B Drug Pricing Program are not only subject to disproportionately greater…